Frequently Asked Questions

Genio is suitable for patients who meet the following criteria:

• Moderate to severe obstructive sleep apnea (AHI 15–65)
• PAP non-adherence (intolerance, failure or refusal must be documented)
• No significant overweight (BMI ≤ 35 kg/m²)
• Percentage of central sleep apnea ≤ 25%
• Other sleep disorders excluded or treated (e.g. RLS / PLM, insomnia)

Please consult your treating physician to assess your eligibility to Genio.

Yes. Genio received CE mark in March 2019 and is approved for use in Europe.

Yes, in Germany and Switzerland, the costs for Genio are covered by health insurance companies if the following conditions are met:

• Moderate to severe obstructive sleep apnea (AHI 15–65)
• PAP non-adherence (intolerance, failure or refusal must be documented)
• No significant overweight (BMI ≤ 35 kg/m²)
• Percentage of central sleep apnea ≤ 25%
• Other sleep disorders excluded or treated (e.g. RLS / PLM, insomnia)

The implantation of the Genio neurostimulator only requires a single incision in the chin fold. The localization of the scar at this point is very discreet, but also depends on the individual tendency to scarring.

The implantable stimulator has been designed to adapt to the patient's anatomy and weighs only 3 grams. As this implant is usually located 2.5 cm below the skin, it is generally not palpable for the patient.

The electrical stimulation cannot be felt. After the start of therapy, your attending physician will help you to gradually adjust the stimulation so that both the treatment result and comfort are optimized throughout the night.

It is important that the patch adheres to the skin so that an optimal signal is transmitted between the wearable component and the implanted neurostimulator. For this reason, it is requested that the area under the chin is free of facial hair.

Yes. The implantable stimulator is placed through a small incision under the chin during a minimally invasive surgical procedure. In Germany patients can generally return home after 3 days. The system is activated after 8 weeks in the clinic and is checked at regular intervals and adjusted as required.

Patients with other active implantable medical devices (AIMD) are contraindicated for Genio.

Stimulation of the hypoglossal nerve has shown clinically significant improvements in the severity of obstructive sleep apnea, daytime sleepiness and sleep-related quality of life. Results may vary from one patient to another.

The Genio system received market approval in 2019 and has since been increasingly used in countries where hypoglossal nerve stimulation is covered by health insurance. This is the case throughout Germany and Switzerland. Hundreds of patients with obstructive sleep apnea are now benefiting from Genio.

And tens of thousands of OSA patients worldwide have already been treated with hypoglossal nerve stimulation.

Genio is suitable for people who are not significantly overweight. The body mass index should be ≤ 35 kg/m².